Medicine
Pharmaceuticals
Product Number : 50242-136-04
Interleukin Inhibitor
Indication
Actemra® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Actemra® (tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Systemic Juvenile Idiopathic Arthritis (SJIA)
Actemra® (tocilizumab) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
Benefit
ACTEMRA RA treatment is available through 2 methods. These options give you the ability to take your medicine in a way that works for you. Both options are proven to help reduce the symptoms of RA. ACTEMRA is available to treat rheumatoid arthritis (RA) as:
Subcutaneous (SC) injection: an injection under the skin that you give yourself at home, or that a caregiver may give you
Intravenous (IV) infusion: liquid medicine given into a vein at a doctor’s office or an infusion clinic